BioDlink Biopharm Co., Ltd. Completes First International Shipment of Bevacizumab to Colombia
Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia.
BioDlink announced the first international shipment of its bevacizumab injection biosimilar to Colombia in partnership with Kexing BioPharm.
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is widely used in the treatment of various cancers, including metastatic colorectal cancer (mCRC) and metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC).
According to industry estimates, bevacizumab injection achieved global sales of USD 8.5 billion in 2023.
Author's summary: BioDlink ships bevacizumab to Colombia.
More News
- West Indies ease past Bangladesh in first T20I
- Budget jitters see construction forecasts plummet
- How to Design and Install the Best Ventilation System for Your Cooking Needs | NorthPennNow
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives
- Sweden’s still ahead in the preparedness game — and now it means business
- How to Choose and Install the Right Bathroom Ventilation System | NorthPennNow
- 5 members of the 2025 Yankees make list of top 50 free agents
- Battlefield 6 REDSEC battle royale to officially launch soon
- Man Utd Failed With £50 Million Mbeumo Alternative
- Three resilient UK multinationals global managers are excited about | Trustnet